Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
New England Journal of Medicine (Impact Factor: 55.87). 01/2007; 356(2):135-47. DOI: 10.1056/NEJMoa062876
Source: PubMed


A single dose of nevirapine during labor reduces perinatal transmission of human immunodeficiency virus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants.
We studied the response to nevirapine-based antiretroviral treatment among women and infants who had previously been randomly assigned to a single, peripartum dose of nevirapine or placebo in a trial in Botswana involving the prevention of the transmission of HIV-1 from mother to child. All women were treated with antenatal zidovudine. The primary end point for mothers and infants was virologic failure by the 6-month visit after initiation of antiretroviral treatment, estimated within groups by the Kaplan-Meier method.
Of 218 women who started antiretroviral treatment, 112 had received a single dose of nevirapine and 106 had received placebo. By the 6-month visit after the initiation of antiretroviral treatment, 5.0% of the women who had received placebo had virologic failure, as compared with 18.4% of those who had received a single dose of nevirapine (P=0.002). Among 60 women starting antiretroviral treatment within 6 months after receiving placebo or a single dose of nevirapine, no women in the placebo group and 41.7% in the nevirapine group had virologic failure (P<0.001). In contrast, virologic failure rates did not differ significantly between the placebo group and the nevirapine group among 158 women starting antiretroviral treatment 6 months or more post partum (7.8% and 12.0%, respectively; P=0.39). Thirty infants also began antiretroviral treatment (15 in the placebo group and 15 in the nevirapine group). Virologic failure by the 6-month visit occurred in significantly more infants who had received a single dose of nevirapine than in infants who had received placebo (P<0.001). Maternal and infant findings did not change qualitatively by 12 and 24 months after the initiation of antiretroviral treatment.
Women who received a single dose of nevirapine to prevent perinatal transmission of HIV-1 had higher rates of virologic failure with subsequent nevirapine-based antiretroviral therapy than did women without previous exposure to nevirapine. However, this applied only when nevirapine-based antiretroviral therapy was initiated within 6 months after receipt of a single, peripartum dose of nevirapine. ( number, NCT00197587 [].).

1 Follower
14 Reads
  • Source
    • "Little is known about the impact of short-term ZDVm exposure on the woman’s subsequent response to ART when started for her own health. In low- and middle-income settings use of single-dose nevirapine (sd-NVP) can have a negative impact on subsequent treatment responses to NVP-containing regimens, with high levels of drug resistance, particularly when ART is initiated within 6–12 months post-sd-NVP exposure [4,5]. However, whereas resistance to NVP requires a single mutation, resistance to ZDV requires multiple sequential mutations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Short-term zidovudine monotherapy (ZDVm) remains an option for some pregnant HIV-positive women not requiring treatment for their own health but may affect treatment responses once antiretroviral therapy (ART) is subsequently started. Data were obtained by linking two UK studies: the UK Collaborative HIV Cohort (UK CHIC) study and the National Study of HIV in Pregnancy and Childhood (NSHPC). Treatment responses were assessed for 2028 women initiating ART at least one year after HIV-diagnosis. Outcomes were compared using logistic regression, proportional hazards regression or linear regression. In adjusted analyses, ART-naive (n = 1937) and ZDVm-experienced (n = 91) women had similar increases in CD4 count and a similar proportion achieving virological suppression; both groups had a low risk of AIDS. In this setting, antenatal ZDVm exposure did not adversely impact on outcomes once ART was initiated for the woman's health.
    BMC Infectious Diseases 03/2014; 14(1):127. DOI:10.1186/1471-2334-14-127 · 2.61 Impact Factor
  • Source
    • "In a meta-analysis, Arrivé et al.26 found that on average 36% of the women treated with sdNVP had detectable NVP resistance several weeks after the treatment and 53% of the children. Other studies have shown that women who are previously treated with sdNVP are more likely to fail therapy if they are later treated with NNRTI-based ART.27 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Access to combination antiretroviral treatment (ART) has improved greatly over recent years. At the end of 2011, more than eight million HIV-infected people were receiving ART in low-income and middle-income countries. ART generally works well in keeping the virus suppressed and the patient healthy. However, treatment only works as long as the virus is not resistant against the drugs used. In the last decades, HIV treatments have become better and better at slowing down the evolution of drug resistance, so that some patients are treated for many years without having any resistance problems. However, for some patients, especially in low-income countries, drug resistance is still a serious threat to their health. This essay will review what is known about transmitted and acquired drug resistance, multi-class drug resistance, resistance to newer drugs, resistance due to treatment for the prevention of mother-to-child transmission, the role of minority variants (low-frequency drug-resistance mutations), and resistance due to pre-exposure prophylaxis.
    Infectious disease reports 06/2013; 5(Suppl 1):e5. DOI:10.4081/idr.2013.s1.e5
  • Source
    • "There is evidence that fewer mutations are selected when other ARVs are added to the SDNVP [Arrive et al., 2007; Chi et al., 2007a]. However, the optimal combination of drugs and best time for treatment initiation in order to create a feasible and effective PMTCT strategy for LICs, still need to be defined [Chi et al., 2007b; Lockman et al., 2007]. In addition to improving the efficacy of PMTCT programmes, the PMTCT coverage needs to be expanded. "

    Microbes, Viruses and Parasites in AIDS Process, 10/2011; , ISBN: 978-953-307-601-0
Show more